Clinical trials: sponsored by Royal Marsden NHS Foundation Trust
Colorectal Cancer, Gastro-oesophageal Adenocarcinoma
Cohort Study to eLucidAte Causes, Behaviour and Outcomes of gastRo Intestinal Tract Cancers in the Young
This study aims to better understand how gastrointestinal (digestive system) cancers develop and how they respond to treatment in young adults, in order to improve ways to prevent, diagnose, and manage these cancers in this age…
- Conditions
- Colorectal Cancer, Gastro-oesophageal Adenocarcinoma, Hepato-Biliary Carcinoma in Situ Nos
- Trial name
- CLARITY (NCT07903571)
- Testing
- Research blood samples
- Volunteers
- 200 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer
Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer
The SAFE-DE study investigates whether circulating tumour DNA (ctDNA) testing can guide adjuvant treatment decisions in patients with stage I breast cancer, identifying those who may be able to avoid chemotherapy after surgery.
- Trial name
- Safe-De (NCT05058183)
- Testing
- ctDNA
- Where
- 13 sites in United Kingdom
- Volunteers
- 800 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Endometrial Carcinoma (EC)
A Study of Short-course Hypofractionated Online-adaptive Radiotherapy for the Post-operative Treatment of Endometrial Cancer: Tolerability and Feasibility
The goal of this clinical trial is to assess the safety and feasibility of using a new form of radiotherapy technology, known as CT online-adaptive radiotherapy, to reduce the number of treatment sessions required in…
- Trial name
- SHORTEN (NCT07675733)
- Testing
- Hypofractionated CT online adaptive radiotherapy (CT-OART) with dose of 30 Gray in 5 fractions, over one and a half weeks
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Solid Tumours, Multiple Myeloma
Phase I Trial of VS-6766 Alone and in Combination With Everolimus
This study is a multi-centre, investigator-initiated, Phase I clinical trial evaluating different dosing schedules of VS-6766, given either alone or in combination with everolimus, in patients with advanced solid tumours or…
- Conditions
- Solid Tumours, Multiple Myeloma, Lung Cancer, Ovarian Cancer
- Trial name
- RAF/MEK (NCT02407509)
- Testing
- VS-6766, Everolimus
- Where
- 3 sites in United Kingdom
- Volunteers
- 104 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer
Prostate Cancer in UK Prisons: A Retrospective Data Analysis
Prostate cancer is the most common cancer affecting men in the United Kingdom (UK) and is the most common cancer in UK prisons. Early diagnosis is vital because treatment is more effective when the disease is detected at an early…
- Trial name
- PRISON-UK (NCT07870707)
- Where
- United Kingdom
- Volunteers
- 9,007 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer
Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
A phase II study of peri-operative anti-PD1 (Zimberelimab) +/- anti-TIGIT (Domvanalimab) in resectable mismatch repair deficient (MMRd)/ high micro-satellite instability (MSI-H) gastric/gastro-oesophageal junctional (GOJ)…
- Conditions
- Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer
- Trial name
- ZODIAC (NCT06250036)
- Testing
- Single agent zimberelimab, Combination zimberelimab + domvanalimab
- Where
- 10 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Triple Negative Breast Cancer, Locally Advanced Breast Cancer
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
This clinical study is aiming to determine the safest doses and schedule for the combination of two drugs named palbociclib and avelumab.
- Conditions
- Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer
- Trial name
- PAveMenT (NCT04360941)
- Testing
- Palbociclib, Avelumab
- Where
- 9 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer
Patient and Provider Perspectives on Genetic Risk Profiling
A qualitative interview study exploring the patient and provider perspectives on the clinical utility of genetic risk profiling in routine clinical practice.
- Trial name
- PPP (NCT07741929)
- Testing
- Qualitative interview
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage I
SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects
This is a single arm, multi-centre, phase II open label study of nivolumab with stereotactic body radiotherapy (SBRT) for early stage non-small cell lung cancer.
- Trial name
- STILE (NCT03383302)
- Testing
- Stereotactic body radiotherapy, Nivolumab
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Pancreatic Cancer
A Phase-II Clinical Trial of Radiotherapy to the Coeliac Plexus to Help Pain in Advanced Pancreatic Cancer
Pain from advanced pancreatic cancer is often difficult to control. This pain commonly occurs when the cancer affects a network of nerves in the abdomen called the coeliac plexus.
- Trial name
- PANCPLEX (NCT07689955)
- Testing
- IMRT
- Volunteers
- 52 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Non Small Cell Lung Cancer, Gastrointestinal Stromal Tumor (GIST)
Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
ctDNA stands for circulating tumour DNA. As ctDNA is released by tumour cells into the blood stream, taking a blood sample and analysing it for ctDNA, can provide a lot of useful information about a patient's cancer.
- Conditions
- Non Small Cell Lung Cancer, Gastrointestinal Stromal Tumor (GIST), Colorectal Cancer, Biliary Tract Cancer
- Trial name
- CURTAIN (NCT07673861)
- Testing
- Marsden360 ctDNA test and GTAB review
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Cervix Cancer
A Study of Pembrolizumab And Platinum With Radiotherapy in Cervix Cancer
Locally advanced cervix cancers (stage 1B-IV) are usually treated with radiotherapy, concomitant cisplatin chemotherapy and brachytherapy.
- Trial name
- PAPAYA (NCT03144466)
- Testing
- Pembrolizumab
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer, Metastasis
Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.
This multi-center, phase II trial will be conducted in men with castration resistant prostate cancer. The aim of the TRAP trial is to test whether a new precise radiotherapy technique called stereotactic body radiotherapy (SBRT)…
- Conditions
- Prostate Cancer, Metastasis, Toxicity Due to Radiotherapy, Circulating Tumour DNA
- Trial name
- TRAP (NCT03644303)
- Testing
- SBRT + ADT
- Where
- 7 sites in United Kingdom
- Volunteers
- 86 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Ovarian Cancer, Peritoneal Cancer
Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR
This is a multi-centre, observational (non-interventional) study, designed to follow patients with advanced ovarian fallopian tube and primary peritoneal cancer, who are receiving Niraparib as maintenance treatment, according to…
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- MONITOR-UK (NCT04295577)
- Testing
- Niraparib
- Where
- 15 sites in United Kingdom
- Volunteers
- 388 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Melanoma, Cancer
Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833
The study is a first in man, dose escalation study to evaluate the safety, tolerability and how the drug works in the body in patients with all solid tumours.
- Trial name
- PanRAF (NCT02437227)
- Testing
- CCT3833
- Where
- 2 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Non Small Cell Lung Cancer
Combination Study of Guadecitabine/ASTX727 and Pembrolizumab
HyPeR is a multi-centre Phase 1 Dose Escalation Study of Guadecitabine (SGI-110)/ASTX727 a Second Generation Hypo-Methylating Agent in Combination with Pembrolizumab (MK3475) in Patients with Refractory Solid Tumours.
- Trial name
- HyPeR (NCT02998567)
- Testing
- Guadecitabine, Pembrolizumab, ASTX727
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Thoracic Tumours
Pembrolizumab and Palliative Radiotherapy in Lung
Lung cancer is the second most common cancer in the UK with around 43,500 new patients diagnosed each year. About 69% of patients are diagnosed with advanced stage disease and at present these patients would be expected to…
- Trial name
- PEAR (NCT02587455)
- Testing
- Pembrolizumab, Radiotherapy
- Where
- 2 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Melanoma
Trial of Pembrolizumab and Radiotherapy in Melanoma
Around 13,000 participants are diagnosed with melanoma in the UK each year and that number is growing quicker than any other cancer.
- Trial name
- PERM (NCT02562625)
- Testing
- Pembrolizumab, Radiotherapy
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer, Triple Negative Breast Cancer
Breast Cancer Evolution During Neoadjuvant Systemic Therapy
BELIEVE is a translational research study that aims to collect samples of breast cancer tissue and blood from individuals undergoing breast cancer treatment (such as chemotherapy, targeted therapy and immunotherapy) before…
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, ER+ Breast Cancer, HER2+ Breast Cancer
- Trial name
- BELIEVE (NCT06681064)
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Metastatic Breast Cancer, ER+ Breast Cancer
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
Analysis of circulating tumour DNA (ctDNA) found in a patient's peripheral blood can identify cancer progression and predict a patient's response to therapy.
- Conditions
- Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
- Trial name
- FAIM (NCT04920708)
- Testing
- Ipatasertib 300mg, Fulvestrant 500g, Palbociclib 75mg-125mg
- Where
- 13 sites in United Kingdom
- Volunteers
- 57 people
- Sponsor
- Royal Marsden NHS Foundation Trust